An upcoming meeting of the US regulator’s Oncologic Drugs Advisory Committee (ODAC) will discuss the benefit/risk profile of Oncopeptides’ (STO: ONCO) Pepaxto (melphalan flufenamide).
The Swedish blood disorder specialist has previously changed its mind about voluntarily withdrawing its New Drug Application (NDA) for Pepaxto, after studying overall survival (OS) data from the Phase III OCEAN study.
Pepaxto was approved under the US Food and Drug Administration’s accelerated approval scheme as a later-line option for people with multiple myeloma.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze